文档介绍：A Global View Ross Underwood MSD Taiwan History of Merck & Co. ? Began as branch of E-Merck, a German fine pany ? 1891 – US subsidiary (Merck & Co.) ? 1897 - $1M in sales (USA) ? 1917 – Due to WWI, US government seizes stock held by E-Merck ? 1918 – Merck & Co. purchases shares from government. Fully owned. Headquarters, New York 1897 History of Merck & Co. ? 1936 – Synthesis of B1 (thiamine) ? 1948 – Synthesis of B12 (anemia) ? 1940 – Streptomycin (tuberculosis) ? 1950 – Non US sales reach $100M ? 1951 – Cortisone (steroid) ? 1958 – Indomethacin – (arthritis) ? 1960 - Chlorothizaide (heart failure) Salesman ’ s sample kit – 1920 ’s History of Merck & Co. ? 1953 – Merger with Sharpe & Dohme, a customer of Merck & Co. ? 1983 - Purchases 50% share of Nippon Merck-Banyu in Japan ? 1986 – Enalapril – 1 st $1B product ? 1987 – Lovastatin – 1 st cholesterol drug ? 1990 – Global sales reach $7 billion Sharp & Dohme product line History of Merck & Co. ? 1992 – Merck establishes MSD Taiwan subsidiary Merck & Co. – At A Glance ? Global employees: 64,000 ? Annual sales: USD 21B ? R&D Spend: USD * ? Research centers: 11 ? Manufacturing Plants: 32 ? Worldwide markets: 150 * % of the world ’ s R&D spend Top panies - Global Taking risk – new drug development ? 1 in 10,000 es a drug ? NT$ 28,000,000,000 cost ? 10-15 years to register ? After 10 years – 50% failure rate ? Competition – within 2 years ? Fewer new drugs ? 18 in 2002 ? 30 in 1998 ? 100 new drugs since 1963 ? R&D spend in 2002: NT$ 98B ? 16% above 2001 ? NT$ 612B over last 10 years ? 9,000 R&D employees ? 11 R&D centers in 7 countries Intellectual property protection (IPR) is critical Environment Response New Drug Development ( Total Cost ~ NT$ 28B) 0 15 Years 2 1 2-5 510 to 20 Substances 5,000 - 10,000 Substances Basic Research Synthesis Examination & Screening Preclinical Tests (Animal) Clinical Tests (Human) Product Surveillance Preclinical Tests (Animal) Phase II